CN111521474A - Method for detecting urea and creatinine in forensic hemolytic blood sample - Google Patents
Method for detecting urea and creatinine in forensic hemolytic blood sample Download PDFInfo
- Publication number
- CN111521474A CN111521474A CN202010387317.0A CN202010387317A CN111521474A CN 111521474 A CN111521474 A CN 111521474A CN 202010387317 A CN202010387317 A CN 202010387317A CN 111521474 A CN111521474 A CN 111521474A
- Authority
- CN
- China
- Prior art keywords
- creatinine
- urea
- ultrafiltrate
- ultrafiltration
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title claims abstract description 164
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 239000004202 carbamide Substances 0.000 title claims abstract description 82
- 229940109239 creatinine Drugs 0.000 title claims abstract description 82
- 210000004369 blood Anatomy 0.000 title claims abstract description 34
- 239000008280 blood Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 34
- 230000002949 hemolytic effect Effects 0.000 title claims abstract description 16
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 82
- 206010018910 Haemolysis Diseases 0.000 claims abstract description 19
- 230000008588 hemolysis Effects 0.000 claims abstract description 19
- 239000012510 hollow fiber Substances 0.000 claims description 19
- 210000002966 serum Anatomy 0.000 claims description 19
- 238000012417 linear regression Methods 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000611 regression analysis Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 abstract description 30
- 238000002306 biochemical method Methods 0.000 abstract description 5
- 102000001554 Hemoglobins Human genes 0.000 abstract description 3
- 108010054147 Hemoglobins Proteins 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 40
- 238000005516 engineering process Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 5
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to a blood sample detection method, and particularly relates to a method for detecting urea and creatinine in a forensic hemolytic blood sample. It solves the color interference generated by hemoglobin in the hemolytic sample, and makes the conventional biochemical method more stable. The method comprises the following steps: step 1, carrying out ultrafiltration treatment on a fully dissolved blood sample by using an ultrafiltration device to obtain ultrafiltrate; step 2, detecting urea and creatinine of the ultrafiltrate; step 3, correcting the content values of urea and creatinine in the ultrafiltrate; and 4, obtaining the content values of urea and creatinine in the forensic hemolysis sample.
Description
Technical Field
The invention belongs to a blood sample detection method, and particularly relates to a method for detecting urea and creatinine in a forensic hemolytic blood sample.
Background
The concentration of urea and creatinine in blood after death has important auxiliary diagnostic significance in the inference of legal medical death causes such as renal failure, fatal high and low temperature injury, hypertonic dehydration and the like, and particularly, the concentration of urea and creatinine plays an important role in diagnosing the renal failure after death. At present, the detection of urea and creatinine in the forensic postmortem examination is mainly based on biochemical methods such as manual detection of a separated serum sample by using a kit and a microplate reader, and the like to detect the concentration of the separated serum sample in body fluid. However, in forensic practice, cadaver blood often fails to separate serum that meets the needs of the test due to hemolysis. Studies have shown that hemolysis will severely interfere with biochemical assays and that stable and useful diagnostic assays cannot be obtained. Therefore, the establishment of the pretreatment of the post-mortem hemolytic blood sample and the effective detection method of creatinine and urea in the treated sample have important forensic practical significance.
For the pretreatment of the hemolyzed blood sample, the hemolyzed blood sample is treated by a high-speed centrifugation and multiple dilution method in the prior art, but the liquid obtained after the hemolyzed blood sample is subjected to high-speed centrifugation still presents a serious red appearance, and the blood sample for biochemical detection cannot be obtained; after the hemolyzed blood sample is diluted by multiple times, although the influence of blood color caused by hemolysis can be reduced, the urea and creatinine are not in direct proportion to the dilution times in the detection, and if the concentration of the diluted sample is lower than the lower limit value of the instrument detection method, the detection cannot be carried out, so that the blood sample diluted by multiple times cannot truly reflect the real concentration of the urea and the creatinine in the original blood.
Disclosure of Invention
The invention provides a method for detecting urea and creatinine in a forensic hemolytic blood sample aiming at the defects in the prior art.
In order to achieve the purpose, the invention adopts the following technical scheme that the method for detecting urea and creatinine in the forensic hemolytic blood sample comprises the following steps.
Step 1, carrying out ultrafiltration treatment on the fully dissolved blood sample by using an ultrafiltration device to obtain ultrafiltrate.
And 2, detecting urea and creatinine in the ultrafiltrate.
And 3, correcting the content values of urea and creatinine in the ultrafiltrate.
And 4, obtaining the content values of urea and creatinine in the forensic hemolysis sample.
Further, an ultrafiltration device; the device is characterized by comprising a hollow fiber ultrafiltration component, a first syringe, a second syringe, a third syringe, a vertical ultrafiltration component and a centrifuge; the first syringe and the second syringe are used for accommodating a sample to be treated for hemolysis, and the third syringe is used for collecting primary ultrafiltrate A; one end of the hollow fiber ultrafiltration component is respectively connected with the first syringe and the third syringe, and the other end of the hollow fiber ultrafiltration component is connected with the second syringe; the vertical ultrafiltration module is used for containing ultrafiltrate A, and the centrifuge is used for centrifuging the ultrafiltrate A in the vertical ultrafiltration module.
Furthermore, the hollow fiber ultrafiltration module adopts MicroKros and mPES type ultrafiltration modules which are produced by American Spectrum Laboratories, and have the aperture of 50 KD and the contact area of 20 cm2。
Further, the vertical ultrafiltration module was made of Amicon type Ultra-0.530KD vertical ultrafiltration module manufactured by Merck Millipore USA.
Furthermore, two ends of the hollow fiber ultrafiltration module are respectively provided with a connecting joint; the inner core of the first connecting joint is connected with the first syringe, and the outer tube of the first connecting joint is connected with the third syringe; the inner core of the second connecting joint is connected with the second syringe.
Further, the step 1 includes the following steps.
Step 1.1, a quantitative (3 mL) total hemolysis sample is extracted by using a first syringe, the first syringe and a second syringe are repeatedly pushed to carry out primary ultrafiltration on liquid in the hollow fiber ultrafiltration component, and at least 500 mu L of light red ultrafiltrate is collected by using a third syringe to obtain ultrafiltrate A.
Step 1.2, transferring 500 mu L of ultrafiltrate A into an inner core of a vertical ultrafiltration component (Amicon Ultra-0.530KD ultrafiltration tube), carrying out secondary ultrafiltration by using a fixed angle rotor centrifuge (14000 g for 10 min), discarding residues of the inner core, and collecting colorless and transparent ultrafiltrate of an outer tube to obtain ultrafiltrate B.
Further, the step 2 comprises the following steps: and (3) detecting the UREA and the creatinine in the ultrafiltrate B by using a biochemical analyzer, a UREA (UREA) determination kit and a Creatinine (CREA) determination kit.
Furthermore, the biochemical analyzer adopts a Heal Force MOL-300 full-automatic biochemical analyzer, the UREA (UREA) determination kit adopts a Shenzhen Meyer biomedical electronics Limited UREA (UREA) determination kit (ultraviolet-glutamic acid dehydrogenase method), and the Creatinine (CREA) determination kit adopts a Shenzhen Meyer biomedical electronics Limited Creatinine (CREA) determination kit (enzyme method).
Further, the step 3 includes the following steps.
Step 3.1, detecting the concentration (N) of urea (Y) and creatinine in the serum when the corpse is not hemolyzed, and respectively marking the concentration (N) of urea (Y) and creatinine as Y1, Y2 and Y3 … …, N1, N2 and N3 … ….
And 3.2, performing freeze-thawing treatment on the whole blood sample corresponding to the serum in the step 3.1, and preparing a full hemolysis sample.
And 3.3, carrying out ultrafiltration treatment on the fully dissolved blood sample by using an ultrafiltration device to obtain ultrafiltrate.
3.4, detecting the urea and the creatinine of the ultrafiltrate by using a biochemical analyzer, a urea determination kit and a Creatinine (CREA) determination kit; the concentrations (M) of urea (X) and creatinine in the ultrafiltrate were obtained and designated X1, X2, X3 … … and … … M1, M2 and M3 … …, respectively.
And 3.5, performing regression analysis (by using SPSS software) on the X and Y values obtained by detecting each group of urea and the M and N values obtained by detecting creatinine, and respectively establishing a urea linear regression equation Y = alpha X + beta and a creatinine linear regression equation N = gamma M +, so as to respectively obtain a value of the urea linear regression equation coefficient alpha and a value of the coefficient beta and a value of the creatinine linear regression equation coefficient gamma and a value of the coefficient gamma.
And 3.6, correcting the content values of the urea and the creatinine in the ultrafiltrate according to the value of the coefficient alpha and the value of the coefficient beta of the urea linear regression equation, the value of the coefficient gamma of the creatinine linear regression equation and the linear regression equation.
Compared with the prior art, the invention has the beneficial effects.
In the aspect of sample pretreatment, the invention firstly adopts hollow fiber ultrafiltration and vertical ultrafiltration components to carry out two-step ultrafiltration treatment on a hemolytic sample, intercepts high molecular weight interference components of the hemolytic sample through an ultrafiltration membrane, and filters target indexes, so that the treated ultrafiltrate is colorless and transparent, the color interference generated by hemoglobin in the hemolytic sample is solved, and the concentration of urea and creatinine in the ultrafiltrate can be more stably and accurately detected by a conventional biochemical method.
In the aspect of detection technology, the full-automatic biochemical analyzer adopted in the invention is used for detecting urea and creatinine in ultrafiltrate, so that detection errors caused by various reasons in the conventional forensic detection can be reduced to the maximum extent, and the urea and creatinine levels in a sample can be accurately detected. Meanwhile, according to the ultrafiltration and detection method in the technology, a correction equation is established, and the influence of hemolysis factors on biochemical detection of urea and creatinine after death in forensic actual work is completely solved.
The invention firstly provides the detection of urea and creatinine by a full-automatic biochemical detection method after two-step ultrafiltration treatment of a forensic hemolytic blood sample. Can truly reflect the concentration of urea and creatinine in a forensic hemolytic blood sample.
Drawings
The invention is further described with reference to the following figures and detailed description. The scope of the invention is not limited to the following expressions.
FIG. 1 is a schematic view of the ultrafiltration device of the present invention.
FIG. 2 is a linear regression plot of ultrafiltrate and serum urea measurements according to the present invention.
FIG. 3 is a linear regression plot of ultrafiltrate and serum creatinine assay values according to the present invention.
Detailed Description
As shown in FIGS. 1-3, the present ultrafiltration method consisted of hollow fiber ultrafiltration modules (MicroKros, mPES, 50000D, 20 cm @)2Spectrum Laboratories, USA) with disposable injector and Amicon Ultra-0.530KD vertical ultrafiltration module (Merck Millipore, USA) to ultrafiltrate the hemolyzed sample, as described in detail below.
Firstly, assembling an ultrafiltration device.
Assembling an ultrafiltration device: the hollow fiber ultrafiltration module and 3 syringes were assembled as shown in fig. 1. Wherein, the first syringe and the second syringe are used as ultrafiltration blood samples, and the third syringe is used for collecting the first step ultrafiltrate.
Secondly, a specific ultrafiltration process.
(1) Using syringe I to extract 3 mL of the whole hemolyzed sample, repeatedly pushing syringes I and II to perform the first ultrafiltration on the liquid in the ultrafiltration module, and using syringe 3 to collect at least 500 μ L of light red ultrafiltrate, i.e. ultrafiltrate A as shown in the figure.
(2) Transferring 500 μ L ultrafiltrate A into Amicon Ultra-0.530KD ultrafiltrate tube inner core, performing second step ultrafiltration at 14000g for 10min by using a fixed angle rotor centrifuge, discarding the inner core residue, and collecting outer tube colorless transparent ultrafiltrate, i.e. ultrafiltrate B as shown in the figure.
And thirdly, detecting urea and creatinine.
And (3) detecting UREA and creatinine in the ultrafiltrate B after the ultrafiltration treatment by using a Heal Force MOL-300 full-automatic biochemical analyzer, a Shenzhen Meyer biomedical electronics Limited UREA (UREA) determination kit (ultraviolet-glutamic acid dehydrogenase method) and a Shenzhen Meyer biomedical electronics Limited Creatinine (CREA) determination kit (enzyme method).
The methods for detecting IgE in a hemolysis sample reported in the past adopt an electrochemiluminescence method for detecting IgE, but the urea and creatinine involved in the technology cannot be detected by the electrochemiluminescence method.
In addition, in the past, the forensic detection of urea and creatinine adopts a 96-well plate detection kit and a microplate reader for detection, but the detection method is mostly operated manually, has large error and is greatly influenced by the technical skill of an operator. The full-automatic biochemical detection instrument adopted in the technology has mature detection technology, stable detection process and little influence of human factors, is a detection method commonly used for laboratory tests in hospitals, and can accurately detect the concentration of urea and creatinine in a sample.
In the domestic field, the method for detecting urea and creatinine by using a full-automatic biochemical detection method after two-step ultrafiltration treatment of a forensic hemolytic blood sample is proposed for the first time. Through years of earlier groping and practice, the method can truly reflect the concentration of urea and creatinine in the forensic hemolytic blood sample.
And fourthly, correcting the contents of urea and creatinine in the ultrafiltrate and the serum.
After the detection is performed by applying the technology, a correction formula needs to be established according to detection samples of respective laboratories, and the method is as follows.
1. The concentration of urea (Y) and creatinine (N) in serum of the corpses without hemolysis are detected and marked as Y1, Y2, Y3 … …, N1, N2 and N3 … … respectively.
2. And (3) performing freeze-thawing treatment on the whole blood sample corresponding to the serum to prepare a fully hemolyzed sample.
3. The hemolyzed sample is treated according to the two-step ultrafiltration method employed in the present technique to obtain an ultrafiltrate.
4. The concentrations (M) of urea (X) and creatinine in the ultrafiltrate were measured and labeled X1, X2, X3 … …, … … M1, M2, and M3 … …, respectively.
Regression analysis is carried out on the X and Y values obtained by detecting each group of urea and the M and N values obtained by detecting creatinine (SPSS software can be used), and a urea linear regression equation Y = alpha X + beta and a creatinine linear regression equation N = gamma M + are respectively established.
For example, as shown in fig. 2 and 3, the correlation between ultrafiltrate and serum urea and creatinine is analyzed by using 39 non-frozen autopsy case heart blood samples, and good correlation (urea r) is obtained2= 0.9651; creatinine r2=0.9795) (fig. 3) and established calibration method for ultrafiltrate, serum urea and creatinineThe process: urea concentration (X) in ultrafiltrate and urea concentration (Y) in non-hemolyzed serum Y =0.9971X + 0.8922; creatinine concentration (M) in ultrafiltrate and creatinine concentration (N) in non-hemolyzed serum N =0.9717M + 21.52.
The detection value in the ultrafiltrate can reflect the level of the ultrafiltrate in serum before hemolysis more reliably after being corrected. If we use the ultrafiltration technology to process the hemolysis sample, and the concentration of urea (X value) and creatinine (M value) in the ultrafiltrate are respectively 13.2mmol/L and 47.17 μmol/L by biochemical method, and the concentration of urea (Y value) and creatinine (N value) in the serum can be estimated to be about 14.05mmol/L and 67.36 μmol/L after the substitution into the calibration formula.
The ultrafiltration technology can separate substances with different molecular weights in the solution according to the pore size of the ultrafiltration membrane. Because of simple and convenient operation, high efficiency and the like, the method is widely applied to a plurality of fields such as water quality purification, hemodialysis, biological sample preparation and the like. According to the invention, according to the fact that the molecular weights of urea and creatinine are very small (far less than 30 KD), a tangential flow hollow fiber ultrafiltration membrane column with the aperture of 50 KD is selected to be combined with a vertical ultrafiltration component with the aperture of 30KD to carry out two-step ultrafiltration treatment, so that hemoglobin and other high molecular weight impurities which generate color interference can be effectively intercepted, the treated sample presents colorless transparent properties, accurate detection by a conventional biochemical method after treatment is ensured, and the serum level before hemolysis is reduced to a great extent by establishing a correction equation.
In the conventional IgE ultrafiltration treatment, because the molecular weight of the IgE is 196000, a tangential flow hollow fiber ultrafiltration membrane column with the pore diameter of 100 KD is selected for carrying out single ultrafiltration treatment on the IgE, and the IgE is retained in an inner core of a hollow fiber ultrafiltration module. In the invention, a tangential flow hollow fiber ultrafiltration membrane column with the aperture of 50 KD is selected to be combined with a vertical ultrafiltration component with the aperture of 30KD to carry out two-step ultrafiltration treatment, and according to the molecular weight of urea and creatinine being less than 30KD, outer core liquid in the ultrafiltration component is reserved in the two-step ultrafiltration treatment for biochemical detection in the next step.
It should be understood that the detailed description of the present invention is only for illustrating the present invention and is not limited by the technical solutions described in the embodiments of the present invention, and those skilled in the art should understand that the present invention can be modified or substituted equally to achieve the same technical effects; as long as the use requirements are met, the method is within the protection scope of the invention.
Claims (9)
1. A method for detecting urea and creatinine in a forensic hemolytic blood sample, comprising the steps of:
step 1, carrying out ultrafiltration treatment on a fully dissolved blood sample by using an ultrafiltration device to obtain ultrafiltrate;
step 2, detecting urea and creatinine of the ultrafiltrate;
step 3, correcting the content values of urea and creatinine in the ultrafiltrate;
and 4, obtaining the content values of urea and creatinine in the forensic hemolysis sample.
2. An ultrafiltration device for carrying out the method of claim 1, wherein: comprises a hollow fiber ultrafiltration component, a first syringe, a second syringe, a third syringe, a vertical ultrafiltration component and a centrifuge; the first syringe and the second syringe are used for accommodating a sample to be treated for hemolysis, and the third syringe is used for collecting primary ultrafiltrate A; one end of the hollow fiber ultrafiltration component is respectively connected with the first syringe and the third syringe, and the other end of the hollow fiber ultrafiltration component is connected with the second syringe; the vertical ultrafiltration module is used for containing ultrafiltrate A, and the centrifuge is used for centrifuging the ultrafiltrate A in the vertical ultrafiltration module.
3. Ultrafiltration device according to claim 2, characterized in that: the hollow fiber ultrafiltration component adopts MicroKros and mPES type ultrafiltration components produced by American Spectrum Laboratories, the aperture is 50 KD, the contact area is 20 cm2。
4. Ultrafiltration device according to claim 2, characterized in that: the vertical ultrafiltration component adopts Amicon type Ultra-0.530KD vertical ultrafiltration component manufactured by Merck Millipore company in America.
5. Ultrafiltration device according to claim 2, characterized in that: the two ends of the hollow fiber ultrafiltration component are respectively provided with a connecting joint; the inner core of the first connecting joint is connected with the first syringe, and the outer tube of the first connecting joint is connected with the third syringe; the inner core of the second connecting joint is connected with the second syringe.
6. The method of claim 1, wherein the method comprises the steps of: the step 1 comprises the following steps:
step 1.1, extracting a quantitative total hemolysis sample by using a first syringe, repeatedly pushing the first syringe and a second syringe to carry out primary ultrafiltration on liquid in a hollow fiber ultrafiltration assembly, and collecting at least 500 mu L of light red ultrafiltrate by using a third syringe to obtain ultrafiltrate A;
and step 1.2, transferring 500 mu L of ultrafiltrate A into an inner core of a vertical ultrafiltration assembly, performing secondary ultrafiltration by using a fixed-angle rotor centrifuge, removing residues of the inner core, and collecting colorless and transparent ultrafiltrate of an outer tube to obtain ultrafiltrate B.
7. The method of claim 1, wherein the method comprises the steps of: the step 2 comprises the following steps: and (3) detecting the urea and the creatinine of the ultrafiltrate B by using a biochemical analyzer, a urea determination kit and a creatinine determination kit.
8. The method of claim 1, wherein the method comprises the steps of: the biochemical analyzer adopts a Heal Force MOL-300 full-automatic biochemical analyzer, the urea determination kit adopts a Shenzhen Merrill biomedical electronics Limited urea determination kit, and the creatinine determination kit adopts a Shenzhen Merrill biomedical electronics Limited creatinine determination kit.
9. The method of claim 1, wherein the method comprises the steps of: the step 3 comprises the following steps:
step 3.1, detecting the concentrations of urea and creatinine in the serum of the corpse without hemolysis, wherein the concentrations are marked as Y1, Y2, Y3 … …, N1, N2 and N3 … … respectively;
step 3.2, performing freeze thawing treatment on the whole blood sample corresponding to the serum in the step 3.1 to prepare a full hemolysis sample;
3.3, carrying out ultrafiltration treatment on the fully dissolved blood sample by using an ultrafiltration device to obtain ultrafiltrate;
3.4, detecting the urea and the creatinine of the ultrafiltrate by using a biochemical analyzer, a urea determination kit and a creatinine determination kit; obtaining the concentrations of urea and creatinine in the ultrafiltrate, which are respectively marked as X1, X2, X3 … …, … … M1, M2 and M3 … …;
step 3.5, carrying out regression analysis on the X and Y values obtained by detecting each group of urea and the M and N values obtained by detecting creatinine, and respectively establishing a urea linear regression equation Y = alpha X + beta and a linear regression equation N = gamma M + of creatinine to respectively obtain the value of the coefficient alpha and the value of the coefficient beta of the urea linear regression equation and the value of the coefficient gamma of the linear regression equation of creatinine;
and 3.6, correcting the content values of the urea and the creatinine in the ultrafiltrate according to the value of the coefficient alpha and the value of the coefficient beta of the urea linear regression equation, the value of the coefficient gamma of the creatinine linear regression equation and the linear regression equation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387317.0A CN111521474A (en) | 2020-05-09 | 2020-05-09 | Method for detecting urea and creatinine in forensic hemolytic blood sample |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387317.0A CN111521474A (en) | 2020-05-09 | 2020-05-09 | Method for detecting urea and creatinine in forensic hemolytic blood sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111521474A true CN111521474A (en) | 2020-08-11 |
Family
ID=71908026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010387317.0A Pending CN111521474A (en) | 2020-05-09 | 2020-05-09 | Method for detecting urea and creatinine in forensic hemolytic blood sample |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111521474A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150260747A1 (en) * | 2012-12-09 | 2015-09-17 | Chromedx Corp. | Automated ultra-filtration system |
| CN110938139A (en) * | 2020-01-20 | 2020-03-31 | 中国医科大学 | Hollow fiber ultrafiltration method for total IgE detection of forensic hemolytic sample |
-
2020
- 2020-05-09 CN CN202010387317.0A patent/CN111521474A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150260747A1 (en) * | 2012-12-09 | 2015-09-17 | Chromedx Corp. | Automated ultra-filtration system |
| CN110938139A (en) * | 2020-01-20 | 2020-03-31 | 中国医科大学 | Hollow fiber ultrafiltration method for total IgE detection of forensic hemolytic sample |
Non-Patent Citations (2)
| Title |
|---|
| 贾宇晴: "溶血对样本中含氮化合物、N 末端脑利钠肽前体死后生化学检测的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 高卫民等: "尿素氮、肌酐和尿酸死后生化学检测的法医学应用", 《中国法医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Coe et al. | Variations in vitreous humor chemical values as a result of instrumentation | |
| Cooper | Methods for determining the amount of glucose in blood | |
| Laessig et al. | The effects of 0.1 and 1.0 percent erythrocytes and hemolysis on serum chemistry values | |
| BR112015026242B1 (en) | Biological fluid collection device and biological fluid separation and testing system | |
| US8548772B2 (en) | Automated method and apparatus for detecting erroneous sample collection in clinical assays | |
| CN107884401A (en) | Eliminate the glucose oxidase assay method of piarhemia interference | |
| CN108918866A (en) | A kind of marker of inflammation POCT combined detection kit suit | |
| US9110008B2 (en) | Method for isotopic analysis of water in bodily fluids | |
| Farah et al. | Explanation of the decrease in alkaline phosphatase (ALP) activity in hemolysed blood samples from the clinical point of view: In vitro study | |
| Nixon et al. | Determination of serum nickel by graphite furnace atomic absorption spectrometry with Zeeman-effect background correction: values in a normal population and a population undergoing dialysis | |
| CN111521474A (en) | Method for detecting urea and creatinine in forensic hemolytic blood sample | |
| CN107884588A (en) | Hemolytic agent for detecting glycosylated hemoglobin and its preparation method and application | |
| Chew et al. | Stable isotopes in avian research: a step by step protocol to feather sample preparation for stable isotope analysis of carbon (δ13C), nitrogen (δ15N), and hydrogen (δ2H). Version 1.1 | |
| CN102866258B (en) | Urinary calculus pathogen diagnosis system and application method thereof | |
| CN110938139B (en) | Hollow fiber ultrafiltration method for detecting total IgE of forensic hemolysis sample | |
| Hisayasu et al. | Determination of plasma and erythrocyte lithium concentrations by atomic absorption spectrophotometry. | |
| CN212246838U (en) | Hollow fiber ultrafiltration device for hemolyzed sample treatment | |
| Tamechika et al. | Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results | |
| CN108614059B (en) | Method for detecting nitrite by using hydrophobic eutectic solvent vortex-assisted dispersion liquid microextraction-high performance liquid chromatography | |
| US7033838B2 (en) | Method for the diagnosis of Helicobacter pylori infection, and a diagnostic kit for performing the method | |
| Fekete et al. | The use of routine laboratory tests in postmortem examinations | |
| CN101779959A (en) | Hirudin vacuum blood collection tube | |
| Sazama et al. | Is antiglycolysis required for routine glucose analysis? | |
| CN113607525B (en) | Vacuum blood collection tube additive for blood digestion and preparation method thereof | |
| US20050261840A1 (en) | Method and apparatus for detecting artifactual output from a chemical analyzer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |
|
| RJ01 | Rejection of invention patent application after publication |